Literature DB >> 6386725

The acute-phase reaction and haematological stress syndrome in vascular disease.

J Stuart.   

Abstract

Both acute and chronic phases of vascular disease are associated with a stress response that includes increased hepatic synthesis of fibrinogen and increased bone marrow release of leucocytes and platelets. A likely humoral mediator of the stress response is interleukin-1 released by reticulo-endothelial cells following their stimulation by fibrinogen degradation fragments D and E. Rheological consequences of the stress response include hyperviscosity of plasma and whole blood and decreased blood filterability. Since blood filterability is influenced by both the plasma fibrinogen concentration and the leucocyte count, it is essential to completely remove these extrinsic contaminants by a pre-filtration step before a true measurement of erythrocyte deformability can be made. Understanding of the pathogenesis of these stress syndromes is also a prerequisite to successful therapeutic control of the rheological abnormality of vascular disease.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6386725

Source DB:  PubMed          Journal:  Int J Microcirc Clin Exp        ISSN: 0167-6865


  4 in total

1.  [Hemorheology and acute phase reaction following thrombendarterectomy of the extracranial carotid artery].

Authors:  M Jung; R Koppensteiner; W Graninger; E Minar; G Kretschmer; H Ehringer
Journal:  Klin Wochenschr       Date:  1988-05-02

2.  Social connectedness is associated with fibrinogen level in a human social network.

Authors:  David A Kim; Emelia J Benjamin; James H Fowler; Nicholas A Christakis
Journal:  Proc Biol Sci       Date:  2016-08-31       Impact factor: 5.349

Review 3.  Erythrocyte rheology.

Authors:  J Stuart
Journal:  J Clin Pathol       Date:  1985-09       Impact factor: 3.411

4.  Erythrocyte deformability in peripheral occlusive arterial disease.

Authors:  D Bareford; G S Lucas; N M Caldwell; P C Stone; S Baar; J Stuart
Journal:  J Clin Pathol       Date:  1985-02       Impact factor: 3.411

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.